ADVANCED TISSUE SCIENCES INC
S-3, EX-5, 2000-09-25
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ADVANCED TISSUE SCIENCES INC, S-3, 2000-09-25
Next: ADVANCED TISSUE SCIENCES INC, S-3, EX-23, 2000-09-25



                                                                     EXHIBIT 5.1


                                               September 25, 2000


Advanced Tissue Sciences, Inc.
10933 North Torrey Pines Road
La Jolla, CA  92037


      Re:      Advanced Tissue Sciences, Inc. Registration Statement on Form S-3
               for 3,494,365 Shares of Common Stock

Ladies and Gentlemen:

     We have acted as counsel to Advanced Tissue Sciences, Inc., a Delaware
corporation (the "Company"), in connection with the registration for resale of
3,494,365 shares of Common Stock (the "Shares"), as described in the Company's
Registration Statement on Form S-3 (the "Registration Statement") filed with the
Securities and Exchange Commission under the Securities Act of 1933, as amended
(the "Act").

     This opinion is being furnished in accordance with the requirements of Item
16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.

     We have reviewed the Company's charter documents, the corporate proceedings
taken by the Company in connection with the original issuance and sale of the
Shares, and a certificate of a Company officer regarding (among other things)
the Company's receipt of consideration upon the original issuance and sale of
the Shares. Based on such review, we are of the opinion that the Shares are duly
authorized, validly issued, fully paid and nonassessable.

     We consent to the filing of this opinion letter as Exhibit 5.1 to the
Registration Statement and to the reference to this firm under the caption
"Legal Matters" in the prospectus which is part of the Registration Statement.
In giving this consent, we do not thereby admit that we are within the category
of persons whose consent is required under Section 7 of the Act, the rules and
regulations of the Securities and Exchange Commission promulgated thereunder, or
Item 509 of Regulation S-K.

     This opinion letter is rendered as of the date first written above and we
disclaim any obligation to advise you of facts, circumstances, events or
developments which hereafter may be brought to our attention and which may
alter, affect or modify the opinion expressed herein. Our opinion is expressly
limited to the matters set forth above and we render no opinion, whether by
implication or otherwise, as to any other matters relating to the Company or the
Shares.

                                            Very truly yours,



                                            BROBECK, PHLEGER & HARRISON LLP




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission